News Alert: U.S. Supreme Court Justices Question CMS’s Legal Basis for Slashing 340B Hospitals’ Drug Reimbursement

The U.S. Supreme Court heard arguments today about the legality of the nearly 30% Medicare Part B drug payment cut for 340B hospitals.

Several U.S. Supreme Court justices asked during a hearing today whether the Centers for Medicare & Medicaid Services (CMS) had statutory authority to single out 340B hospitals for a nearly 30% cut in Medicare Part B drug reimbursement

Read More »

340B Providers Take Center Stage Before U.S. Supreme Court Today

The U.S. Supreme Court is hearing arguments this morning in a lawsuit challenging CMS's nearly 30% cut in 340B hospitals' drug reimbursement.

The U.S. Supreme Court is hearing arguments this morning in a lawsuit challenging the nearly 30% cut since 2018 in what Medicare Part B pays hospitals for 340B-purchased physician administered drugs.

Arguments in American Hospital Association v. Becerra

Read More »

Clovis Oncology Reverses Decision to Use Kalderos’ 340B Pricing-as-Rebate System

Clovis Oncology has decided for now not to implement Kalderos’ 340B Pay service to pay 340B ceiling prices as rebates instead of as discounts.

Drug manufacturer Clovis Oncology has decided for now not to implement drug discount management company Kalderos’ 340B Pay service to let drug companies pay 340B ceiling prices as back-end rebates instead of as front-end discounts, Kalderos said late

Read More »

U.S. House GOP Conference Chair Stefanik Backs Protecting 340B Hospitals from Losing Eligibility During Pandemic

U.S. House GOP Conference Chair Elise Stefanik (N.Y.) is backing a bill to protect hospitals from losing their 340B eligibility due to pandemic-related changes in patient and payer mix.

Elise Stefanik, the third highest-ranking Republican in the U.S. House, is backing a bill to protect hospitals from losing their 340B eligibility due to pandemic-related changes in patient and payer mix.

Stefanik (R-N.Y.) announced her co-sponsorship of

Read More »

Peter Welch, Long-Time 340B Advocate in the U.S. House, Announces Run for Senate

U.S. Rep. Peter Welch (D-Vt.), a long-time 340B advocate, is running for the U.S. Senate next year.

U.S. Rep. Peter Welch (D-Vt.), who has backed 340B covered entities in several policy battles, is running to succeed his fellow Democrat Patrick Leahy in the U.S. Senate.

Senate President Pro Tempore Leahy, 81, announced on Nov. 15

Read More »

UCB Becomes Ninth Drug Manufacturer to Announce 340B Contract Pharmacy Limits

Belgian-based UCB is the ninth drug company to impose limits on 340B pricing involving contract pharmacies.

Belgian-based pharmaceutical manufacturer UCB this morning became the ninth drug company to impose limits on 340B pricing involving contract pharmacies.

Hospitals reported getting letters and an FAQ from UCB today by email announcing that, effective Dec. 13

Read More »

HRSA Weighs in on Recent 340B Contract Pharmacy Court Decisions

HRSA says it is pleased with two court decision regarding the 340B contract pharmacy program, but "respectfully disagrees with” and “continues to evaluate its options” about a third decision.

The U.S. Health Resources and Services Administration (HRSA) said this morning it “respectfully disagrees with” and “continues to evaluate its options” about a federal district judge’s Nov. 5 finding that drug manufacturers Novartis and United Therapeutic’s 340B contract

Read More »

CaptureRx Announces Over 120 New Improvements

SPONSORED CONTENT

A little over 2 years ago, CaptureRx launched Cumulus 4.0 (C4) with the goal of delivering the most robust and compliant 340B platform in the industry while allowing for continuous improvements to be implemented with ease. Since the time of launch, CaptureRx has added over 120 new enhancements and upgrades to its Cumulus platform helping organizations improve productivity and take their 340B

Read More »

Carole Johnson Appears to be Leading Candidate to Run HRSA

A screen capture of a video of White House COVID-19 Testing Coordinator Carole Johnson during a briefing on the pandemic. Johnson reportedly will be named the next HRSA administrator.

After a 10-month delay, it looks like we may be getting close to the appointment of a permanent leader of the U.S. Health Resources and Services Administration (HRSA), the federal agency that runs the 340B drug pricing program.

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors